Insider and congress filings

Quest Diagnostics Incorporated (DGX)

NYSE · Healthcare · 387 insider transactions · 74 congress trades · last filed 3 days agoS&P 500

13
Open-market insider filings shown
1d
Median delay on the insider filings, in business days
within the two business day rule
0 buys·13 sells
Purchases and sales in the filings shown
Get a push when an insider at Quest Diagnostics Incorporated trades.

Free on iOS and Android.

About Quest Diagnostics Incorporated

from the company's filings and listing, as of Oct 24, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
James E. Davis
Employees
51,500
Listed since
Dec 17, 1996
Market value
$26.7B
Price to earnings (12 mo)
23.8
Net income per share, as reported (12 mo)
$10.26
Dividend yield
1.40%

www.questdiagnostics.com

Earnings

6 reported quarters · next on Feb 9, 2027
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 22, 2026$3.00$2.87$3.1B$3.1BEPS beatRevenue in line
Q2 FY2026reported Jul 23, 2026$3.12$2.82$3.0B$3.0BEPS beatRevenue beat
Q1 FY2026reported Apr 21, 2026$2.50$2.37$2.9B$2.8BEPS beatRevenue beat
Q4 FY2025reported Feb 10, 2026$2.42$2.36$2.8B$2.8BEPS beatRevenue beat
Q3 FY2025reported Oct 21, 2025$2.60$2.50$2.8B$2.7BEPS beatRevenue beat
Q2 FY2025reported Jul 22, 2025$2.62$2.57$2.8B$2.7BEPS beatRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Apr 6, 2026
ExecutiveSalaryStock awardsOtherTotal
James E. DavisChairman, Chief Executive Officer and President$1.3M$8.8M$5.5M$15.5M
Sam A. SamadExecutive Vice President and Chief Financial Officer$693K$2.2M$1.5M$4.4M
Catherine T. DohertyExecutive Vice President, Regional Businesses$643K$1.7M$1.2M$3.6M
Karthik KuppusamySenior Vice President, Clinical Solutions$568K$1.1M$916K$2.6M
Michael E. PrevoznikSenior Vice President and General Counsel$550K$1.1M$882K$2.6M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$2.0B9,275,411+1.1%8.43%
Vanguard Capital Management LLC$1.5B7,233,394+1.2%6.58%
Vanguard Portfolio Management LLC$1.3B6,131,045+0.8%5.57%
State Street Corp$1.2B5,516,643+2.5%5.02%
T. Rowe Price Associates, Inc.$1.2B5,444,986-13.5%4.95%
Boston Partners$1.0B4,744,473+18.3%4.31%
JPMorgan Chase & Co.$748.6M3,520,438-8.5%3.20%
Geode Capital Management, LLC$662.6M3,137,873+1.7%2.85%
Morgan Stanley$521.5M2,460,497-0.8%2.24%
Edgepoint Investment Group Inc.$476.4M2,247,568+0.2%2.04%
Dimensional Fund Advisors LP$421.4M1,988,048+2.0%1.81%
Bank of America Corp$410.2M1,935,133+10.4%1.76%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Know when the next DGX filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

13 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
J. E. DavisCEO and PresidentSold · scheduled10,000$242.72$2.4MSep 1, 2026filed Sep 3, 20262d
Michael E. PrevoznikSVP & General CounselSold · scheduled · 3 lines22,677$243.11$5.5MAug 28, 2026filed Aug 31, 20261d
Mark E. DelaneySVP & Chief Commercial OfficerSold · scheduled1,600$235.18$376KJul 28, 2026filed Jul 29, 20261d
Karthik KuppusamySVP, Clinical SolutionsSold · scheduled8,147$200.00$1.6MJun 4, 2026filed Jun 8, 20262d
J. E. DavisCEO and PresidentSold · scheduled10,000$194.14$1.9MJun 1, 2026filed Jun 2, 20261d
Karthik KuppusamySVP, Clinical SolutionsSold2,628$204.86$538KMar 4, 2026filed Mar 6, 20262d
Patrick PlewmanSVP for Diagnostic ServicesSold · scheduled2,855$206.21$589KMar 5, 2026filed Mar 6, 20261d
Michael E. PrevoznikSVP & General CounselSold · scheduled3,878$206.21$800KMar 5, 2026filed Mar 6, 20261d
Catherine T. DohertyEVP, Regional BusinessesSold · scheduled5,558$206.21$1.1MMar 5, 2026filed Mar 6, 20261d
Patrick PlewmanSVP for Diagnostic ServicesSold · scheduled410$207.73$85KMar 3, 2026filed Mar 4, 20261d
J. E. DavisCEO and PresidentSold · scheduled10,000$212.52$2.1MMar 2, 2026filed Mar 4, 20262d
Michael E. PrevoznikSVP & General CounselSold · scheduled526$207.73$109KMar 3, 2026filed Mar 4, 20261d
Catherine T. DohertyEVP, Regional BusinessesSold · scheduled632$207.73$131KMar 3, 2026filed Mar 4, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Wright Lassiter IIIDirectorOther Form 4 entry (see filing)6Oct 21, 2026
Karthik KuppusamySVP, Clinical SolutionsOther Form 4 entry (see filing)33Oct 21, 2026
Vicky B. GreggDirectorStock award63Oct 21, 2026
Sam SamadExecutive Vice President & CFOStock award90Oct 21, 2026
Robert B. CarterDirectorOther Form 4 entry (see filing)10Oct 21, 2026
Mark E. DelaneySVP & Chief Commercial OfficerOther Form 4 entry (see filing)25Oct 21, 2026
Timothy L. MainDirectorOther Form 4 entry (see filing)18Oct 21, 2026
Patrick PlewmanSVP for Diagnostic ServicesOther Form 4 entry (see filing)41Oct 21, 2026
Timothy C. WentworthDirectorStock award135Oct 1, 2026
Michael E. PrevoznikSVP & General CounselGift1,000Aug 28, 2026
Michael E. PrevoznikSVP & General CounselOption exercise22,677Aug 28, 2026
Mark E. DelaneySVP & Chief Commercial OfficerOther Form 4 entry (see filing)34Jul 22, 2026
Wright Lassiter IIIDirectorOther Form 4 entry (see filing)6Jul 22, 2026
Sam SamadExecutive Vice President & CFOStock award102Jul 22, 2026
Timothy L. MainDirectorOther Form 4 entry (see filing)21Jul 22, 2026
Patrick PlewmanSVP for Diagnostic ServicesOther Form 4 entry (see filing)46Jul 22, 2026
Vicky B. GreggDirectorStock award72Jul 22, 2026
Robert B. CarterDirectorOther Form 4 entry (see filing)11Jul 22, 2026
Karthik KuppusamySVP, Clinical SolutionsOther Form 4 entry (see filing)37Jul 22, 2026
Timothy C. WentworthDirectorStock award144Jul 1, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in DGX

20 disclosures of 74 on record · median 31d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Julie JohnsonJointFiled lateStockSale$1,001 - $15,000+37.6%After the saleS&P 500 +11.7% · +25.9 pts vs S&P 500Oct 30, 2025Aug 5, 2026279d
Julie JohnsonJointFiled lateStockPurchase$1,001 - $15,000+37.6%S&P 500 +11.7% · +25.9 pts vs S&P 500Oct 30, 2025Aug 5, 2026279d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+23.7%S&P 500 +19.8% · +3.9 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+22.7%S&P 500 +20.3% · +2.4 pts vs S&P 500Mar 30, 2026Jul 21, 2026113d
Ro KhannaStockSale$1,001 - $15,000+17.7%After the saleS&P 500 +11.2% · +6.5 pts vs S&P 500Feb 17, 2026Mar 9, 202620d
Ro KhannaStockPurchase$1,001 - $15,000+32.7%S&P 500 +9.5% · +23.2 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
Julia LetlowFiled lateStockPurchase$1,001 - $15,000+36.9%S&P 500 +37.9% · -1.0 pts vs S&P 500Apr 28, 2025Jan 13, 2026260d
Julia LetlowFiled lateStockSale$1,001 - $15,000+40.7%After the saleS&P 500 +19.8% · +20.9 pts vs S&P 500Jul 24, 2025Jan 13, 2026173d
Julie JohnsonJointStockSale$1,001 - $15,000+35.3%After the saleS&P 500 +11.2% · +24.1 pts vs S&P 500Nov 3, 2025Dec 11, 202538d
Carol D. MillerStockSale$1,001 - $15,000+39.7%After the saleS&P 500 +35.5% · +4.2 pts vs S&P 500Mar 10, 2025Apr 11, 202532d
Ro KhannaStockPurchase$1,001 - $15,000+60.0%S&P 500 +27.1% · +32.8 pts vs S&P 500Jan 17, 2025Feb 6, 202520d
Ro KhannaStockPurchase$1,001 - $15,000+49.6%S&P 500 +27.3% · +22.3 pts vs S&P 500Nov 12, 2024Dec 5, 202423d
Ro KhannaStockPurchase$1,001 - $15,000+50.8%S&P 500 +29.7% · +21.0 pts vs S&P 500Nov 15, 2024Dec 5, 202420d
Ro KhannaStockExchangeNot capturedn/aMar 5, 2024Mar 6, 20241d
Ro KhannaStockSaleNot capturedn/aMar 5, 2024Mar 6, 20241d
Tommy TubervilleJointStockSale (Partial)$15,001 - $50,000+73.2%After the saleS&P 500 +62.2% · +11.0 pts vs S&P 500Jan 3, 2024Feb 14, 202442d
Ro KhannaStockPurchase$1,001 - $15,000+75.9%S&P 500 +66.4% · +9.5 pts vs S&P 500Dec 4, 2023Jan 4, 202431d
Ro KhannaStockPurchase$1,001 - $15,000+79.3%S&P 500 +66.5% · +12.8 pts vs S&P 500Dec 5, 2023Jan 4, 202430d
Ro KhannaStockPurchase$1,001 - $15,000+85.9%S&P 500 +81.8% · +4.1 pts vs S&P 500Oct 31, 2023Nov 8, 20238d
Ro KhannaStockSale$1,001 - $15,000+90.3%After the saleS&P 500 +70.4% · +19.9 pts vs S&P 500Sep 6, 2023Oct 6, 202330d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

"Not captured" means the band or the transaction type on the original report is missing from our data.

Every Congress trade in DGX, filterable by party, chamber, type and account.

Members of Congress reporting a position

1 member · estimate, as of Oct 21, 2026

1 member reports a position (estimated). The largest estimated position is in the $1,001 - $15,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
Gilbert Ray Cisneros, Jr.Democrat · House$1,001 - $15,000<0.1%

Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling DGX?

Across the 13 most recent open-market filings shown here, 0 were purchases and 13 were sales. 12 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded DGX?

Julie Johnson, Alan Armstrong, Ro Khanna, Julia Letlow, Carol D. Miller and Tommy Tuberville disclosed DGX transactions in the filings shown here.

Which members of Congress hold DGX?

1 member of Congress reports a position in DGX in the estimate we hold as of Oct 21, 2026. The estimated position belongs to Gilbert Ray Cisneros, Jr. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is DGX in the S&P 500 or the Nasdaq 100?

Quest Diagnostics Incorporated is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are DGX trades disclosed?

Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 31 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track